Lessons from natural molecules

Nature

Volumn 432, Issue 7019, 2004, Pages 829-837

  Clardy, Jon ^a   Walsh, Christopher ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERIVATIVES; LABORATORIES; PROFESSIONAL ASPECTS; SYNTHESIS (CHEMICAL);

NATURAL PRODUCTS; NATURAL-PRODUCT ISOLATION; THERAPEUTIC APPLICATIONS;

MOLECULES;

ATORVASTATIN; ATROPINE; BENZODIAZEPINE; CALICHEAMICIN; COCAINE; DISCODERMOLIDE; DYNEMICIN A; DYSIDIOLIDE; EPIBATIDINE; EPOXOMICIN; FLUOXETINE; FUMAGILLIN; HEMIASTERLIN; IMATINIB; LACTACYSTIN; LEINAMYCIN; NATURAL PRODUCT; PACLITAXEL; PHOSPHORAMIDIC ACID; RAPAMYCIN; SALINOSPORAMIDE; SAXITOXIN; SILDENAFIL; SIMVASTATIN; SODIUM CHLORIDE; STAUROSPORINE; TELOMESTATIN; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

MEDICINE;

BIOSYNTHESIS; CHEMICAL MODIFICATION; CORRELATION ANALYSIS; DERIVATIZATION; DRUG FORMULARY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; FUTUROLOGY; HERBAL MEDICINE; HUMAN; LABORATORY; NATURAL SCIENCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; STRUCTURE ANALYSIS; TECHNIQUE;

ANIMALS; BIOLOGICAL FACTORS; DRUG INDUSTRY; HUMANS; OXIDATION-REDUCTION; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 11144311139     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03194     Document Type: Review

References (82)

1. Newman, D. J., Cragg, G. M. & Snader, K. M. The influence of natural products upon drug discovery. Nat. Prod. Rep. 17, 215-234 (2000).
2. Newman, D. J., Cragg, G. M., Holbeck, S. & Sausville, E. A. Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. Curr. Cancer Drug Targets 2, 279-308 (2002).
3. Newman, D. J., Cragg, G. M. & Snader, K. M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66, 1022-1037 (2003).
4. Altmann, K.-H. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr. Opin. Chem. Biol. 5, 424-431 (2001).
5. Mickel, S. J. et al. Large-scale synthesis of the anti-cancer marine natural product (+) - discodermolide. Part 1: Synthetic strategy and preparation of a common precursor. Org. Proc. Res. Dev. 8, 92-100 (2004).
6. Sheldrick, G. M., Jones, P. G., Kennard, O., Williams, D. H. & Smith, G. A. Structure of vancomycin and its complex with acetyl-D-alanyl-D-alanine. Nature 271, 223-225 (1978).
7. Williamson, M. P. & Williams, D. H. Structure revision of the antibiotic vancomycin. Use of nuclear Overhauser effect difference spectroscopy. J. Am. Chem. Soc. 103, 6580-6585 (1981).
8. Furasaki, A. et al. The crystal and molecular structure of staurosporine, a new alkaloid from a Streptomyces strain. J. Chem. Soc. Chem. Commun. 800-801 (1978).
9. Sehgal, S. N., Baker, H. & Vezina, C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. 28, 727-732 (1975).
10. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P. & McPhail, A. T. The isolation and structure of taxol, a novel antileukemic and antitumor agent. J. Am. Chem. Soc. 93, 2325-2327 (1971).
11. Pindur, U., Kim, Y. S. & Mehrabani, F. Advances in indolo[2,3-a]carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Curr. Med. Chem. 6, 29-69 (1999).
12. Carson, C. C. 3rd Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Curr. Urol. Rep. 4, 488-496 (2003).
13. Wong, D. T. & Bymaster, F. P. Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors. Adv. Exp. Med. Biol. 363, 77-95 (1995).
14. Roth, B. D. The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog. Med. Chem. 40, 1-22 (2002).
15. Kurzrock, R., Kantarjian, H. M., Druker, B. J. & Talpaz, M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. 138, 819-830 (2003).
16. Lee, M. D., Dunne, T. M., Chang, C. C., Morton, G. O. & Borders, D. B. Calicheamicins, a novel family of antitumor antibiotics. J. Am. Chem. Soc. 109, 3464-3466 (1987).
17. Konishi, M. et al. Crystal and molecular structure of dynemicin A: a novel 1,5-diyn-3-ene antitumor antibiotic. J. Am. Chem. Soc. 112, 3715-3716 (1990).
18. Thorson, J. S. et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr. Pharm. Des. 6, 1841-1879 (2000).
19. Scotto, K. W. ET-743: more than an innovative mechanism of action. Anticancer Drugs 13 (Suppl. 1), S3-6 (2002).
20. Aune, G. J., Furuta, T. & Pommier, Y. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs 13, 545-555 (2002).
21. Liu, S., Widom, J., Kemp. C. W., Crews, C. M. & Clardy, J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282, 1324-1327 (1998).
22. Meng, L., Kwok, B. H., Sin, N. & Crews, C. M. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 59, 2798-2801 (1999).
23. Fenteany, G. et al. Inhibition of proteasome activities and sub unit-specific amino-terminal threonine modification by lactacystin. Science 268, 726-731 (1995).
24. Feling, R. H. et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew. Chem. Int. Edn Engl. 42, 355-357 (2003).
25. Kim, M. Y., Gleason-Guzman, M., Izbicka, E., Nishioka, D. & Hurley, L. H. The differential biological effects of telomestatin and TMPPyP4 can be attributed to their selectivity for interaction with intramolecular and intermolecular G-quadruplex structures. Cancer Res. 63, 3247-3256 (2003).
26. Choi, J., Chen, J., Schreiber, S. L. & Clardy, J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239-242 (1996).
27. Gunasekera, S. P., Gunasekera, M., Longley, R. E. & Schulte, G. K. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J. Org. Chem. 55, 4912-4915 (1991).
28. Talpir, R., Benayahu, Y., Kashman, Y., Pannell, L. & Schleyer, M. Hemiasterlin and geodiamolide TA: two new cytotoxic peptides from the marine sponge Hemiasterella minor. Tetrahedron Lett. 35, 4453-4456 (1994).
29. Anderson, R. J., Coleman, J. E., Andersen, R. J. & Roberge, M. Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother. Pharmacol. 39, 223-226 (1997).
30. Schantz, E. J. et al. The structure of saxitoxin. J. Am. Chem. Soc. 93, 7344-7345 (1975).
31. Yotsu-Yamashita, M. et al. The structure of zetekitoxin AB, a saxitoxin analog from the Panamanian golden frog Atelopus zeteki: a potent sodium-channel blocker. Proc. Natl Acad. Sci. USA 101, 4346-4351 (2004).
32. Rinehart, K. L. et al. Ecteinascidins 729, 743, 743, 759A, 759B and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J. Org. Chem. 55, 4512-4515 (1990).
33. Boghaert, E. R. et al. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Clin. Cancer Res. 10, 4538-4549 (2004).
34. DiJoseph, J. F. et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103, 1807-1814 (2004).
35. Boldi, A. M. Libraries from natural product-like scaffolds. Curr. Opin. Chem. Biol. 8, 281-286 (2004).
36. Gunasekera, S. P., McCarthy, P. J., Kelly-Borges, M., Lobkovsky, E. & Clardy, J. Dysidiolide: a novel protein phosphatase inhibitor from the Caribbean sponge Dysidea etheria de Laubenfels. J. Am. Chem. Soc. 118, 8759-8760 (1996).
37. Brohm, D. et al. Natural products are biologically validated starting points in structural space for compound library development: solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. Angew. Chem. Int. Edn Engl. 41, 307-311 (2002).
38. Schreiber, S. L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964-1969 (2000).
39. Burke, M. D. & Schreiber, S. L. A planning strategy for diversity-oriented synthesis. Angew. Chem. Int. Edn Engl. 43, 46-58 (2004).
40. Burke, M. D., Berger, E. M., Schreiber, S. L. Generating diverse skeletons of small molecules combinatorially. Science 302, 613-618 (2004).
41. Walsh, C. Antibiotics: Actions, Origins, Resistance (ASM, Washington, 2003).
42. Hubbard, B., Walsh, C. Vancomycin assembly: Nature's way. Angew. Chem. Int. Edn Engl. 730-765 (2003).
43. Schwarzer, D., Firking, R., Marahiel, M. A. Nonribosomal peptides: from genes to products. Nat. Prod. Rep. 20, 275-287 (2003).
44. Walsh, C., Freel Meyers, C. L., Losey, H. C. Antibiotic glycosyltransferases: antibiotic maturation and prospects for reprogramming. J. Med. Chem. 46, 3425-3436 (2003).
45. Wendt, K. U., Schulz, G. E., Corey, E. J., Liu, D. R. Enzyme mechanisms for polycyclic triterpene formation. Angew. Chem. Int. Edn Engl. 39, 2812-2835 (2000).
46. Whittington, D. A. et al. Bornyl diphosphate synthase: structure and strategy for carbocation manipulation by a terpenoid cyclase. Proc. Natl. Acad. Sci. USA 99, L5375-15380 (2002).
47. Rawlings, B. J. Type I polyketide biosynthesis in bacteria (part A). Nat. Prod. Rep. 18, 190-230 (2001).
48. Rawlings, B. J. Type I polyketide biosynthesis in bacteria (part B). Nat. Prod. Rep. 18, 231-281 (2001).
49. Kohli, R. & Walsh, C. Enzymology of acyl chain macrocyclization in natural product biosynthesis. Chem. Commun. 297-307 (2003).
50. Schwecke, T. et al. The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. Proc. Natl Acad. Sci. USA 92, 7839-7843 (1995).
51. Ahlert, J. et al. The calicheamycin gene cluster and its iterative type I enediyne PKS. Science 297, 1173-1176 (2002).
52. Liu, W., Christensen, S. D., Standage, S. & Shen, B. Biosynthesis of the enediyne antitumor antibiotic C-1027. Science 297, 1170-1173 (2002).
53. Shen, B., Liu, W. & Nonaka, K. Enediyne natural products: biosynthesis and prospects towards engineering novel antitumor agents. Curr. Med. Chem. 10, 2317-2325 (2003).
54. Zerbe, K. et al. Crystal structure of OxyB, a cytochrome P450 implicated in an oxidative phenol coupling reaction during vancomycin biosynthesis. J. Biol. Chem. 277, 47476-47485 (2002).
55. Pylypenko, O., Vitali, F., Zerbe, K., Robinson, J. A. & Schlichting, I. Crystal structure of OxyC, a cytochrome P450 implicated in an oxidative C-C coupling reaction during vancomycin biosynthesis. J. Biol. Chem. 278, 46727-46733 (2003).
56. Walker, K. & Croteau, R. Taxol biosynthetic genes. Phytochemistry 58, 1-7 (2001).
57. Chau, M., Jennewein, S., Walker, K. Croteau, R. Taxol biosynthesis: molecular cloning and characterization of a cytochrome P450 taxoid 7 beta-hydroxylase. Chem. Biol. 11, 663-672 (2004).
58. Jennewein, S., Long, R. M., Williams, R. M. & Croteau, R. Cytochrome p450 taxadiene 5 alpha-hydroxylase, a mechanistically unusual monooxygenase catalyzing the first oxygenation step of taxol biosynthesis. Chem. Biol. 11, 379-387 (2004).
59. Yadav, G., Ghokale, R. S. & Mohanty, D. Computational approach for prediction of domain organization and substrate specificity of modular polyketide synthases. J. Mol. Biol. 328, 335-363 (2003).
60. Eppelman, K., Stachelhaus, T. & Marahiel, M. A. Exploitation of the selectivity-conferring code of nonribosomal peptide synthetases for the rational design of novel peptide antibiotics. Biochemistry 42, 9718-9716 (2002).
61. Lu, W., Leimkuhler, C., Oberthur, M., Kahne, D. & Walsh, C. AknK is an L-2-deoxyfucosyltransferase in the biosynthesis of the anthracycline aclacinomycin. Biochemistry 43, 4548-4558 (2004).
62. Losey, H. C. et al. Incorporation of glucose analogs by glycosyltransferases GtfE and GtfD from the vancomycin biosynthetic pathway to generate variant glycopeptides. Chem. Biol. 9, 1305-1314 (2002).
63. MendeZ, C. & Salas, J. A. Altering the glycosylation pattern of bioactive compounds. Trends Biotechnol. 19, 449-456 (2001).
64. McDaniel, R. et al. Multiple genetic modifications of the erythromycin gene cluster to produce a library of novel 'unnatural' natural products. Proc. Natl Acad. Sci. USA 96, 1846-1851 (1999).
65. Tang, L. & McDaniel, R. Construction of desosamine containing polyketide libraries using a glycosyltransferase with broad substrate specificity. Chem. Biol. 8, 547-555 (2001).
66. Wohlleben, W. & Pelzer, S. New compounds by combining modern genomics and old-fashioned mutasysnthesis. Chem. Biol. 9, 1163-1166 (2002).
67. Huang, Q., Roessner, C. A., Croteau, R. & Scott, A. I. Engineering E. coli for the synthesis of taxadiene, a key intermediate in the biosynthesis of taxol. Biorg. Med. Chem. 9, 2237-2242 (2001).
68. Martin, V. J., Pitera, D. J., Withers, S. T., Newman, J. D. & Keasling, J. D. Engineering a mevalonate pathway in E.coli for production of terpenoids. Nature Biotechnol. 21, 796-802 (2003).
69. Ondeyka, J. G. et al. Nodulisporic acids C, C1, and C2: a series of D-ring-opened nodulisporic acids from the fungus Nodulisporium sp. J. Prod. 66, 121-124 (2003).
70. Brady, S. F., Bondi, S. M. & Clardy, J. The guanacastepenes: a highly diverse family of secondary metabolites produced by an endophytic fungus. J. Am. Chem. Soc. 123, 9900-9901 (2001).
71. Fuller, R. W. et al. A pentahalogenated monoterpene from the red alga Portieria hornemanni produces a novel cytotoxicity profile against a diverse panel of human tumor cell lines. J. Med. Chem. 35, 3007-3011 (1992).
72. Piel, J. Metabolites from symbiotic bacteria. Nat. Prod. Rep. 21, 519-538 (2004).
73. Luesch, H., Yoshida, W. Y., Moore, R. E., Paul, V. J. & Corbett, T. H. Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula. J. Am. Chem. Soc. 123, 5418-5423 (2001).
74. Edwards, D. J. et al. Structure and biosynthesis of the jamaicamides, new mixed polyketide-peptide neurotoxins from the marine cyanobacterium Lyngbya majuscula. Chem. Biol. 11, 817-833 (2004).
75. Gerth, K., Bedorf, N., Hofle, G., Irschik, H. & Reichenbach, H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J. Antibiot. (Tokyo) 49, 560-563 (1996).
76. Sasse, F., Steinmetz, H., Heil, J., Hofle, G. & Reichenbach, H. Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. J. Antibiot. (Tokyo) 53, 879-885 (2000).
77. Pace, N. R. A molecular view of microbial diversity and the biosphere. Science 276, 734-740 (1997).
78. Kaeberlein, T., Lewis, K. & Epstein, S. S. Isolating 'uncultivable' microorganisms in pure culture in a simulated natural environment. Science 296, 1127-1129 (2002).
79. Wang, G. Y. et al. Novel natural products from soil DNA libraries in a streptomycete host. Org. Lett. 2, 2401-2404 (2000).
80. Brady, S., Chao, C. J. & Clardy, J. New natural product families from an eDNA cluster. J. Am. Chem. Soc. 124, 9968-9969 (2002).
81. Zazopoulos, E. et al. A genomics-guided approach for discovering and expressing cryptic metabolic pathways. Nature Biotechnol. 21, 187-190 (2003).
82. Jennewein, S., Wildung, M. R., Chau, M., Walker, K. & Croteau, R. Random sequencing of an induced Taxus cell cDNA library for identification of clones involved in Taxol biosynthesis. Proc. Natl Acad. Sci. USA 101, 9149-9154 (2004).